Xeris Biopharma Holdings, Inc. (XERS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Xeris Biopharma is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its primary commercial products are Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). The company is also developing XP-8121, a once-weekly subcutaneous levothyroxine.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $60.1 million | $40.6 million |
| Net Loss | $(9.2) million | $(19.0) million |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.14) |
| Cash and Cash Equivalents | $58.4 million | $62.7 million |
| Total Debt (Net) | $229.8 million | $232.1 million |
| Accumulated Deficit | $(681.1) million | $(636.0) million |
| Operating Cash Flow | $(10.0) million | $(20.3) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 47.9% year-over-year, driven primarily by Recorlev, which saw a 140.9% increase ($25.5M vs. $10.6M) due to prescription volume growth. Gvoke revenue rose 25.7%, while Keveyis revenue declined 12.7% due to unfavorable net pricing.
- Improved Loss Profile: Net loss narrowed by 51.4% to $9.2 million, and operating loss improved by 78.3% to $3.1 million, reflecting revenue growth outpacing expense increases.
- Expense Trends: Selling, general, and administrative (SG&A) expenses increased 14.7% to $44.0 million, largely due to investments in the Recorlev commercial organization. Research and development (R&D) expenses remained flat at $7.8 million.
- Debt Conversions: In March 2025, $3.2 million of 2025 Convertible Senior Notes were converted into common stock. The remaining $12.0 million of these notes were converted in April 2025 (post-period).
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash resources ($58.4 million) are sufficient to sustain operations for at least the next 12 months. The company expects to continue incurring net losses.
- Debt Structure: The company carries significant debt obligations, including $200 million in 2029 Term Loans (effective interest rate ~11.4%) and $33.6 million in 2028 Convertible Notes (8.0% interest). The 2029 Loans mature on March 5, 2029, but could mature earlier if convertible notes are not redeemed or extended.
- Risks: Key risks include the ability to raise additional capital on acceptable terms, reliance on single-source suppliers, and the impact of macroeconomic conditions (interest rates, inflation) on borrowing costs. The company faces potential dilution if it raises equity or converts debt.
- Operational Updates: The company completed the implementation of a new Enterprise Resource Planning (ERP) system in Q1 2025 to improve financial controls.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $58.4 million cash balance against the projected burn rate and upcoming debt maturities.
- Debt Covenants: Review the specific covenants in the Amended and Restated Credit Agreement regarding the maturity of the 2029 Loans and conditions for extension.
- Recorlev Pricing: Monitor the sustainability of Recorlev's volume growth given the noted unfavorable net pricing trends in Q1 2025.
- Convertible Note Status: Confirm the full conversion of the remaining 2025 Convertible Notes in April 2025 and its impact on future interest expense.
- Inventory Levels: Assess the increase in inventory ($52.7M) relative to sales velocity to ensure no obsolescence risks.